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Background/aim: The aim of this study was to investigate the association of lipoprotein(a) [Lp(a)] with the severity of coronary heart
disease (CHD) in Han Chinese people.
Materials and methods: Six hundred and seventy-nine patients with angiographically defined CHD were enrolled in this cross-sectional
study. Fasting lipids were measured, and the severity of CHD was quantitatively assessed for each patient according to the number of
stenotic coronary branches and the Gensini scoring system.
Results: The levels of Lp(a), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), very low-density lipoprotein cholesterol
(VLDL-C), and apolipoprotein (apo) B100 increased, while high-density lipoprotein cholesterol (HDL-C) and apoAI decreased
significantly with the number of stenotic vessels. The levels of Lp(a) increased and HDL-C and apoAI decreased significantly with
the Gensini scores. The logistic regression analyses showed that Lp(a) and HDL-C were independently associated with the number of
stenotic coronary vessels after adjusting for age, weight, body mass index, sex, smoking, alcohol consumption, hypertension, diabetes,
triglycerides, TC, LDL-C, VLDL-C, apoAI, and apoB100. However, only Lp(a) was independently associated with the Gensini scores
after adjustment.
Conclusion: Our data indicate that Lp(a) might be a useful marker in predicting the severity of coronary heart disease.
Key words: Lipoprotein(a), coronary heart disease, severity, Gensini score, lipid

1. Introduction
At the beginning of the twentieth century, coronary heart
disease (CHD) and cerebrovascular disease were only
responsible for less than 10% of all deaths worldwide.
Over the past few decades, the epidemic of cardiovascular
disease has become the leading cause of morbidity and
mortality in developed countries and in some developing
countries, including China (1–3). The risk factors for CHD
include dyslipidemia, metabolic syndrome, atherogenic
diet, unhealthy lifestyle, and gene mutations or
polymorphisms (4–6). Of these risk factors, dyslipidemia
is considered to be the most important determinant and
accounts for at least 50% of the population-attributable
risk for CHD (7). Conventionally, increases in low-density
lipoprotein cholesterol (LDL-C), total cholesterol (TC),

and triglycerides (TG) and/or decreases in high-density
lipoprotein cholesterol (HDL-C) were considered as the
major causal factors for CHD (8). Clinical guidelines
recommended that the primary therapy be targeted to
LDL-C and non-HDL-C reduction, and that the other lipid
indices be used as secondary or supplementary targets
(8,9). However, lipoprotein(a) [Lp(a)], as an emerging risk
factor for CHD, is getting more and more attention among
epidemiologists and cardiologists.
Lp(a) was originally discovered by Kåre Berg in
1963 (10). It has received intensive investigation in the
last few decades regarding its important role in the
occurrence of CHD (11–14). This LDL-like particle
is of particular interest because a large hydrophilic
glycoprotein [apolipoprotein(a), apo(a)], which has
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highly homologous regions as plasminogen, is covalently
linked to apolipoprotein (apo) B100 via a disulfide bond.
Lp(a) has long been considered as an atherogenic and
prothrombotic lipoprotein due to its unique structure
(15), which was also supported by experimental proof
that Lp(a) can inhibit the key positive feedback step of the
plasmin-mediated conversion from Glu-plasminogen to
Lys-plasminogen (16) and the activation of pericellular
plasminogen in human umbilical vein endothelial cells,
THP-1 monocytes, and macrophages (17).
A series of studies have suggested a causal link between
circulating Lp(a) and CHD (11–14). The plasma levels
of Lp(a) have also been associated with the severity of
CHD (18–20). Both Lp(a) levels and percentage of hyperLp(a) increased linearly with the number of significantly
diseased vessels in elderly men and women (18). Among
the recognized risk factors of atherosclerosis, Budde et
al. (19) found that only Lp(a) plasma levels correlated
significantly with the vessel score, stenosis score, and
extent score. Habib et al. (20) demonstrated that Lp(a)
levels were associated with more severe and diffuse
blockage of the coronary vessels in a Saudi population.
However, other studies failed to demonstrate a positive
correlation between the increasing Lp(a) concentrations
and the severity of CHD (21,22). Although Labeur et al.
(21) found a significant association between Lp(a) and the
severity of coronary stenosis in Belgian patients, it was
attenuated after adjusting for other confounding factors,
and Imhof et al. (22) did not find an appreciable association
between Lp(a) and the severity of coronary atherosclerosis
in a European population. Hence, the association between
plasma Lp(a) levels and the severity of CHD is still obscure
and needs to be further explored.
The plasma levels of Lp(a) vary widely across
populations and ethnicities. Data on the association
between Lp(a) and CHD were largely derived from
Caucasians, and few studies were conducted in low- and
middle-income countries like China, where more than
80% of the global burden of cardiovascular disease occurs
(1,2). In this study, we sought to investigate the relationship
between Lp(a) levels and the severity of CHD in a cohort
of Chinese patients.
2. Materials and methods
2.1. CHD patients
This study was designed as a hospital-based investigation
at the Affiliated Hospital of North Sichuan Medical College
(Nanchong, China). A total of 679 consecutive patients
diagnosed with CHD by coronary angiography were
enrolled in this study between May 2011 and April 2014.
Patients taking lipid-lowering drugs were excluded from
the study. Patients with valvular disease, cardiomyopathy,
renal or hepatic dysfunction, active inflammatory disease,
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myocarditis, and malignant disease were also excluded.
Written consent was provided by all the participants or
their guardians prior to their participation in the study.
Our study was approved by the ethics committee of North
Sichuan Medical College.
2.2. Coronary angiography
Standard coronary angiography was performed using
the Judkins technique with an Allura Xper FD20 (Philips
Medical Systems Nederland B.V., the Netherlands).
Two experienced cardiologists who were unaware of the
patients’ biochemical statuses were employed to evaluate
the severity of CHD. There were at least four views of the
left coronary system and two views of the right coronary
artery. CHD was diagnosed in patients who had coronary
stenosis greater than 50% in at least one major coronary
artery. Those with stenosis less than 50% in any of the
major coronary arteries were excluded from this study.
2.3. Definition
Body mass index (BMI) was calculated by dividing
weight by height squared (kg/m2). Smokers were patients
with regular cigarette smoking. Drinkers were patients
with regular alcohol consumption. Patients with systolic/
diastolic blood pressure higher than 140/90 mmHg or
active use of antihypertensive drugs were diagnosed with
hypertension. Patients with fasting glucose levels above
126 mg/dL or active use of antidiabetic drugs or insulin
were diagnosed with diabetes.
2.4. Biochemical measurement
Fasting blood samples were taken on the first morning
of the hospitalization day when patients did not take any
lipid-lowering drugs. Blood samples were immediately
transported to the Department of Clinical Laboratory of
the Affiliated Hospital of North Sichuan Medical College
for measurements of Lp(a), TC, LDL-C, HDL-C, very lowdensity lipoprotein cholesterol (VLDL-C), TG, apoB100,
and apoAI. The measurements were carried out using an
automatic clinical chemistry analyzer (Beckman Coulter
UniCel DxC 800 Synchron, USA).
2.5. Statistical analysis
Data were expressed as mean ± standard deviation (SD)
unless otherwise stated. Continuous variables were tested
for normality and log transformation was carried out for
those data with nonnormal distribution. All statistical
analyses were carried out using SPSS 13.0 (SPSS Inc.,
Chicago, IL, USA). The differences among the groups
divided by the number of stenotic vessels or the tertile of
the Gensini scores were analyzed by one-way analysis of
variance (ANOVA). The associations between the variables
and the severity of CHD were analyzed by univariate
and multivariate ordinal logistic regression analysis. The
results of logistic regression analysis were expressed as the
odds ratio (OR) with 95% confidence interval (95% CI). P
< 0.05 was considered to be significant in all the analyses.
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3. Results
3.1. Clinical characteristics of the study population
The study population consisted of 679 CHD patients with
a mean age of 63.28 ± 10.40 years, a mean BMI of 24.37
± 2.95, and a mean Lp(a) level of 325.24 ± 354.77 mg/L.
The majority of the patients were males (71.13%) and
nondiabetic (85.13%). Around half of the patients were
smokers (47.28%) or hypertensive (48.16%) (Table 1).
To evaluate the effects of Lp(a) and other variables on
the severity of CHD, the patients were divided into three
groups according to the number of stenotic vessels (group
1: single-vessel stenosis; group 2: double-vessel stenosis;
group 3: multivessel stenosis) or the tertile of the Gensini
scores [group 1: ≤33rd percentile (scores 1–12); group 2:
33rd to 66th percentile (scores 13–32); group 3: ≥66th
percentile (scores ≥33)]. The mean age, Lp(a), TC, LDL-C,
VLDL-C, and apoB100 and the percentages of males and
hypertensive and diabetic patients increased while HDL-C
and apoAI levels decreased significantly with the number
of stenotic vessels. When comparisons of the variables
were conducted among the tertile of the Gensini scores,
the mean age, Lp(a) levels, and percentages of males and
diabetic patients increased while HDL-C and apoAI levels
decreased significantly with the tertile of the Gensini
scores.
Of all the variables, age, Lp(a), HDL-C, and apoAI had
consistently significant associations with the severity of
CHD evaluated by either the number of stenotic vessels or
the Gensini scores.
3.2. Ordinal logistic regression analysis for the
associations between lipid parameters and the number
of stenotic vessels
Univariate logistic regression analyses showed that the
number of stenotic vessels was significantly associated with
age, male sex, diabetes mellitus, higher levels of TC, LDL-C,
Lp(a), and apoB100 and lower levels of HDL-C and apoAI
(P < 0.05 for all) (Table 2). Subsequent multiple logistic
regression analyses revealed that the number of stenotic
vessels was independently associated with age, male sex,
diabetes mellitus, Lp(a), and HDL-C concentrations after
adjusting for the possible confounding variables including
TC, LDL-C, apoAI, and apoB100 (P < 0.05 for all) (Table
2).
3.3. Ordinal logistic regression analyses for the
associations between lipid parameters and the tertile of
the Gensini scores
Univariate logistic regression analyses showed that the
tertiles of the Gensini scores were significantly associated
with age, male sex, diabetes mellitus, smoking, Lp(a),
HDL-C, and apoAI levels (P < 0.05 for all) (Table 3).
Subsequent multiple logistic regression analyses revealed
that the tertiles of the Gensini scores were independently

associated with age, diabetes mellitus, and Lp(a) after
controlling for other possible confounding variables
including sex, smoking, HDL-C, and apoAI (P < 0.05 for
all) (Table 3).
4. Discussion
In the present study, we found that Lp(a) increased
proportionally with the number of stenotic coronary
branches and the tertile of the Gensini scores; patients
with higher Lp(a) concentrations were more likely to
have multiple stenotic vessels and high Gensini scores.
In the multivariate logistic regression, Lp(a) and HDL-C
were significantly associated with the risk of multibranch
coronary artery stenosis after adjusting for age, sex,
diabetes, TC, LDL-C, apoAI, and apoB100, but only Lp(a)
remained significant when the tertile of the Gensini scores
was used as the dependent variable after adjustment. Our
results indicate that Lp(a) may be a stronger predictor for
the severity of CHD than HDL-C and other conventional
lipid parameters.
Some previous studies also demonstrated a positive
association between Lp(a) and the severity of CHD
(18,19). Of the conventional lipid parameters, Budde et al.
(19) found that only the plasma levels of Lp(a) correlated
significantly with the coronary vessel score, stenosis score,
and extent score. Furthermore, both Lp(a) levels and the
percentage of high Lp(a) were found to be linearly and
significantly related to the number of stenotic vessels in
elderly men and women (18). However, the association
between plasma Lp(a) levels and the severity of CHD has
not been fully clarified. Although the fully adjusted OR for
CHD was 3.3 for the patients in the upper quartile of the
Lp(a) distribution compared to the bottom quartile, Imhof
et al. (17) did not find an appreciable association between
Lp(a) and the severity of CHD. This controversy can partly
be explained by the differences in the experimental design,
stenosis evaluation, and characteristics and ethnicities
of patients. In addition, the different medical treatments
among studies may also account for these inconsistent
results. Our results suggest that Lp(a) could be a good
predictor for the severity of CHD and that Lp(a) may play
an important role in the development of coronary plaques
in Han Chinese people.
The association between Lp(a) and the severity of
coronary stenosis is probably linked to its proatherogenic
and prothrombotic properties (23). Lp(a) is a unique
lipoprotein particle that consists of a LDL-like particle and
an apo(a) molecule, which is covalently linked to apoB100
by a disulfide bond. According to the Adult Treatment
Panel III Guidelines (8) and the 2013 ACC/AHA blood
cholesterol guidelines (9) of the United States, LDL is the
most atherogenic lipoprotein in blood and is considered
as the major cause of CHD. Lp(a) is supposed to be as
atherogenic as LDL since it contains a LDL-like particle
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321 (47.28)

202 (29.75)

327 (48.16)

101 (14.87)

Smokers, n (%)

Drinkers, n (%)

Hypertension, n (%)

Diabetes, n (%)

1.58 ± 1.10

4.17 ± 1.06

2.36 ± 0.81

0.99 ± 0.33

0.83 ± 0.56

1.00 ± 0.21

0.75 ± 0.25

TG, mmol/L

TC, mmol/L

LDL-C, mmol/L

HDL-C, mmol/L

VLDL-C, mmol/L

ApoAI, g/L

ApoB100, g/L

0.78 ± 0.25

1.02 ± 0.21

0.91 ± 0.67

1.01 ± 0.35

2.44 ± 0.81

4.34 ± 1.10

1.66 ± 1.14

320.79 ± 352.69

28 (14.81)

76 (40.21)

61 (32.28)

97 (51.32)

144 (76.19)

24.37 ± 3.12

64.13 ± 9.14

62.81 ± 9.84

0.77 ± 0.27

0.97 ± 0.21

0.84 ± 0.59

0.94 ± 0.31

2.45 ± 0.93

4.23 ± 1.21

1.66 ± 1.30

393.63 ± 400.99

48 (21.62)

116 (52.25)

64 (28.83)

111 (50.00)

170 (76.58)

24.10 ± 3.04

63.84 ± 9.85

65.36 ± 10.25

0.008*

0.017*

0.014*

0.01*

0.002*

0.002*

0.099

0.001*

0.001*

0.033*

0.670

0.095

0.001*

0.343

0.429

0.001*

0.73 ± 0.23

1.02 ± 0.19

0.81 ± 0.50

1.01 ± 0.31

2.31 ± 0.72

4.13 ± 0.94

1.54 ± 0.93

272.72 ± 311.06

25 (10.87)

106 (46.09)

72 (31.30)

94 (40.87)

154 (66.96)

24.72 ± 2.83

65.36 ± 9.78

61.94 ± 10.51

0.75 ± 0.24

1.02 ± 0.21

0.80 ± 0.55

1.04 ± 0.36

2.35 ± 0.77

4.19 ± 1.00

1.53 ± 1.19

316.20 ± 348.04

29 (12.95)

113 (50.45)

64 (28.57)

111 (49.55)

154 (68.75)

24.25 ± 3.02

63.93 ± 9.68

63.09 ± 10.72

33rd to 66th
percentile (n = 224)

0.77 ± 0.28

0.96 ± 0.20

0.88 ± 0.62

0.93 ± 0.30

2.41 ± 0.93

4.20 ± 1.22

1.69 ± 1.17

387.94 ± 393.17

47 (20.89)

108 (48.00)

66 (29.33)

116 (51.56)

175 (77.78)

24.08 ± 3.01

63.95 ± 9.53

64.84 ± 9.78

0.223

0.001*

0.236

0.002*

0.462

0.744

0.255

0.002*

0.007*

0.648

0.805

0.052

0.025*

0.144

0.321

0.011*

≥66th percentile
P-value
(n = 225)

CHD, Coronary heart disease; BMI, body mass index; Lp(a), lipoprotein(a); TG, triglycerides; TC, total cholesterol; LDL-C, low-density lipoprotein cholesterol; HDL-C, highdensity lipoprotein cholesterol; VLDL-C, very low-density lipoprotein cholesterol; apoAI, apolipoprotein AI; apoB100, apolipoprotein B100. *: Significant difference (P < 0.05).

0.71 ± 0.23

1.01 ± 0.20

0.76 ± 0.42

1.02 ± 0.32

2.22 ± 0.69

4.01 ± 0.85

1.47 ± 0.86

325.24 ± 354.77 271.74 ± 303.55

25 (9.33)

135 (50.37)

77 (28.73)

113 (42.16)

Lp(a), mg/L

Lipid parameters

483 (71.13)

Men, n (%)

169 (63.06)

24.58 ± 2.76

24.37 ± 2.95

BMI, kg/m

65.16 ± 9.91

64.46 ± 9.68

61.89 ± 10.67

Weight, kg

2

P-value

≤33rd percentile
(n = 230)

Multivessel
stenosis (n = 222)

Single-vessel
stenosis (n = 268)

Double-vessel
stenosis (n = 189)

Tertile of the Gensini scores

Number of stenotic vessels

63.28 ± 10.40

Total patients
(n = 679)

Age, years

Demographic parameters

Variables

Table 1. Clinical characteristics of the CHD patients by the number of stenotic vessels or the tertile of the Gensini scores.
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Table 2. Ordinal logistic regression analysis of the number of stenotic vessels (dependent variable) and other independent variables.
Variables

Univariate logistic regression
OR

95% CI

Multivariate logistic regression
P-value

OR

95% CI

P-value

1.04

1.03–1.06

0.000*

1.39–2.72

0.000*

1.54–3.49

0.000*

Anthropometric parameters
Age, years

1.03

1.01–1.04

0.000*

Weight, kg

0.99

0.97–1.01

0.196

BMI, kg/m2

0.96

0.90–1.02

0.155

Sex, n (%)
Female

1.00 (ref)

Male

1.73

1.00 (ref)
1.27–2.37

0.001*

0.98–1.71

0.070

0.76–1.39

0.871

0.78–1.36

0.830

1.95

Smokers, n (%)
No

1.00 (ref)

Yes

1.29

Drinkers, n (%)
No

1.00 (ref)

Yes

1.03

Hypertension, n (%)
No

1.00 (ref)

Yes

1.03

Diabetes, n (%)
No

1.00 (ref)

Yes

2.12

1.43–3.15

0.000*

1.00 (ref)

1.13

0.99–1.28

0.063

2.31

Lipid parameters
TG, mmol/L
TC, mmol/L

1.18

1.04–1.35

0.013*

1.24

0.89–1.73

0.206

LDL-C, mmol/L

1.33

1.12–1.59

0.001*

1.33

0.86–2.06

0.199

0.51

0.26–0.99

0.046*

HDL-C, mmol/L

0.55

0.36–0.85

0.007*

VLDL-C, mmol/L

1.23

0.95–1.57

0.111

ApoAI, g/L

0.44

0.22–0.87

0.019*

0.66

0.23–1.90

0.437

ApoB100, g/L

2.09

1.19–3.65

0.010*

1.86

0.60–5.77

0.284

Lp(a), mg/L

1.26

1.11–1.43

0.000*

1.23

1.08–1.41

0.002*

ApoAI: Apolipoprotein AI; ApoB100: apolipoprotein B100; BMI: body mass index; 95% CI: 95% confidence interval; HDL-C: highdensity lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; Lp(a): lipoprotein(a); OR: odds ratio; TC: total cholesterol;
TG: triglycerides; VLDL-C: very low-density lipoprotein cholesterol. *: Significant association (P < 0.05).

(24). In addition, Lp(a) is also thought to be prothrombotic
(25). The molecular structure of plasminogen includes a
signal peptide, Kringles 1–5, a protease domain, and a tail,
whereas apo(a) has the homologous signal peptide, Kringle
4, Kringle 5, and a protease-like domain and does not
contain Kringles 1–3 and the tail. The structural homology
between apo(a) and plasminogen suggests that Lp(a) can
promote thrombosis. Several studies have shown that Lp(a)
can inhibit the activation of plasminogen by competing
for the binding of activators to plasminogen, and can
consequently attenuate fibrinolysis (17,26). Lp(a) may also

promote thrombosis by a mechanism independently of
plasminogen (27). The number of Kringle 4 type 2 (KIV-2)
repeats and the molecular size of apo(a) are also associated
with CHD (28). The molecular size of apo(a) varies from
300 kDa to 800 kDa across populations. A metaanalysis
demonstrated that individuals with small apo(a) isoforms
(≤22 repeats) had 2-fold higher CHD risk compared to
those with larger apo(a) isoforms (>22 repeats) (28).
It is worth mentioning that age, sex, and diabetes
had a significant relationship with the severity of CHD
after adjusting for other possible confounding factors in
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Table 3. Ordinal logistic regression analysis of the tertile of the Gensini scores (dependent variable) and other independent
variables.
Variables

Univariate logistic regression
OR

95% CI

Multivariate logistic regression
P-value

OR

95% CI

P-value

1.03

1.01–1.04

0.000*

0.89–1.91

0.175

0.88–1.77

0.216

1.90

1.27–2.84

0.002*

0.77

0.46–1.31

0.343

0.45

0.18–1.13

0.090

1.27

1.11–1.44

0.000*

Anthropometric parameters
Age, years

1.02

1.01–1.03

0.004*

Weight, kg

0.99

0.97–1.01

0.185

BMI, kg/m2

0.95

0.89–1.00

0.058

Sex, n (%)
Female

1.00 (ref)

Male

1.48

1.00 (ref)
1.09–2.01

0.012*

1.04–1.81

0.025*

0.70–1.29

0.738

0.08–1.40

0.677

1.30

Smokers, n (%)
No

1.00 (ref)

Yes

1.37

1.00 (ref)
1.25

Drinkers, n (%)
No

1.00 (ref)

Yes

0.95

Hypertension, n (%)
No

1.00 (ref)

Yes

1.06

Diabetes, n (%)
No

1.00 (ref)

Yes

1.80

1.21–2.68

0.004*

1.00 (ref)

TG, mmol/L

1.18

0.90–1.54

0.243

TC, mmol/L

1.05

0.92–6.05

0.464

LDL-C, mmol/L

1.12

0.94–1.32

0.210

Lipid parameters

HDL-C, mmol/L

0.63

0.42–0.93

0.021*

VLDL-C, mmol/L

1.19

0.93–1.52

0.177

ApoAI, g/L

0.34

0.17–0.68

0.002*

ApoB100, g/L

1.65

0.95–2.87

0.078

Lp(a), mg/L

1.25

1.11–1.42

0.000*

ApoAI: Apolipoprotein AI; ApoB100: apolipoprotein B100; BMI: body mass index; 95% CI: 95% confidence interval; HDL-C:
high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; Lp(a): lipoprotein(a); OR: odds ratio; TC:
total cholesterol; TG: triglycerides; VLDL-C: very low-density lipoprotein cholesterol. *: Significant association (P < 0.05).

the present study and that these indices are classical risk
factors for the development of CHD. The severity of CHD
increases steeply with age in Indonesian males and females
(29). The reason why the severity of stenosis increases with
age is that age reflects the progressive accumulation of
coronary atherosclerosis (8). At any given age, males are
at a greater risk for coronary disease compared to females
(30). Risk in females lags approximately 10 to 15 years
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behind that of males (8). The reasons for sex difference
in CHD risk are not fully understood. One possible
mechanism could be the earlier onset of risk factors in
males: for example, elevations of LDL-C, triglycerides, and
blood pressure, and/or reduction of HDL-C (8). However,
the Framingham Heart Study showed that the differences
in absolute risk between males and females cannot be
explained entirely by the differences of the conventional
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risk factors (8). A growing body of literature revealed
that the risk for CHD increases substantially with type
2 diabetes mellitus (31,32). Furthermore, the mortality
rate in diabetic subjects who have experienced CHD is
much higher than that in nondiabetic subjects (33). In our
study, the patients with diabetes mellitus had more severe
narrowing of the three major coronary arteries than did
the nondiabetic patients, which indicates that diabetes is
not only associated with the onset of CHD but also with
the development of CHD.
Although LDL-C is considered as the major cause of
CHD in both the Adult Treatment Panel III Guidelines
(8) and the 2013 ACC/AHA blood cholesterol guidelines
(9) of the United States, our study shows that LDL-C is a
poor predictor for the increased number of stenotic vessels
(Table 2) and the Gensini score (Table 3). On the other
hand, HDL-C levels decreased with increasing Gensini
scores after adjusting for other possible confounding
factors (Table 3). Epidemiological evidence links low
levels of HDL-C to increased CHD morbidity and
mortality, whereas high HDL-C levels conversely convey
reduced risk (34). Taken together with our findings, it can
be safely concluded that HDL-C is negatively associated
with the severity of CHD. Furthermore, decreased
HDL-C was found to be an independent predictor for
enhanced inflammation and endothelial activation, which
are both critical in the pathogenesis of atherosclerosis
and atherosclerosis-related complications (35). The
mechanistic relationship between low HDL-C levels and
the severity of CHD has not been fully elucidated. One
theory could be that HDL promotes efflux of cholesterol
from foam cells in reverse cholesterol transport (36), and,
on the other hand, has antioxidant and antiinflammatory
properties that inhibit atherogenesis (37).

It should be pointed out that our study has several
limitations. First, the Syntax scoring system was not
employed to assess the severity of CHD in the present
study for the reason that our angiographic data were more
suitable to calculate the Gensini scores. The clinical risk
factors are included in the calculation of Syntax scores
and hence it can objectively evaluate the severity of
CHD. In addition, the Syntax scores can also accurately
distinguish patients with or without a clinical outcome and
could accurately predict the cardiovascular risk without
under- or overestimating risk (38). Second, we did not
carry out a clinical follow-up of the studying population.
Well-designed long-term prospective trials are needed
to determine the exact role of Lp(a) in the development
of CHD. Third, the patients included in this study are
exclusively Han Chinese people, and therefore our
findings may not apply to other ethnic groups. However,
one advantage of our study is that the severity of CHD was
assessed by both the number of stenotic vessels and the
Gensini scores. Our results could be more accurate since
most of previous studies only used one method to evaluate
the severity of CHD (39,40).
In conclusion, we observed an orderly increase in
Lp(a) levels with the increasing number of stenotic vessels
and Gensini scores, and an independent association
between Lp(a) and the severity of CHD after adjusting for
other possible confounding factors. Lp(a) may be a useful
predictor for the severity of CHD in the Han Chinese
population.
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